Kaposi sarcoma herpesvirus (KSHV) seems to exploit almost every known cancer pathway to promote tumorigenesis. Activation of the canonical Wnt–β-catenin pathway can now be added to its list of conquests (pages 300–306).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Infectious Agents and Cancer Open Access 01 May 2020
-
KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development
Infectious Agents and Cancer Open Access 02 February 2007
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Kimberly Homer
References
Chang, Y. et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865–1869 (1994).
Boshoff, C. & Weiss, R.A. AIDS-related malignancies. Nat. Rev. Cancer 2, 373–382 (2002).
Fujimuro, M. et al. A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat. Med. 9, 300–306 (2003).
Polakis, P. Wnt signaling and cancer. Genes Dev. 14, 1837–1851 (2000).
Kielman, M.F. et al. Apc modulates embryonic stem-cell differentiation by controlling the dosage of β-catenin signaling. Nat. Genet. 32, 594–605 (2002).
Ballestas, M.E., Chatis, P.A. & Kaye, K.M. Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science 284, 641–644 (1999).
Friborg, J., Kong, W., Hottiger, M.O. & Nabel, G.J. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402, 889–894 (1999).
Radkov, S.A., Kellam, P. & Boshoff, C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat. Med. 6, 1121–1127 (2000).
Verschuren, E.W., Klefstrom, J., Evan, G.I. & Jones, N. The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2, 229–241 (2002).
Bais, C. et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 391, 86–89 (1998).
Montaner, S. et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3, 23–36 (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boshoff, C. Kaposi virus scores cancer coup. Nat Med 9, 261–262 (2003). https://doi.org/10.1038/nm0303-261
Issue Date:
DOI: https://doi.org/10.1038/nm0303-261
This article is cited by
-
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
Infectious Agents and Cancer (2020)
-
KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development
Infectious Agents and Cancer (2007)
